Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aura Biosciences, Inc. (AURA : NSDQ)

• Company Description    Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. Number of Employees: 109

• Price / Volume Information    Yesterday's Closing Price: $6.19 Daily Weekly Monthly 20 Day Moving Average: 319,750 shares Shares Outstanding: 62.12 (millions) Market Capitalization: $384.52 (millions) Beta: 0.45 52 Week High: $12.38 52 Week Low: $4.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.12% -1.08% 12 Week -12.32% -15.84% Year To Date -24.70% -33.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 80 GUEST STREET - BOSTON,MA 02135 USA ph: 617-500-8864 fax: - ir@aurabiosciences.com http://www.aurabiosciences.com

• General Corporate Information    Officers Elisabet de los Pinos - Chief Executive Officer;President David Johnson - Chairman of the Board of Directors Amy Elazzouzi - Senior Vice President Giovanni Mariggi - Director Antony Mattessich - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05153U107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 62.12 Most Recent Split Date: (:1) Beta: 0.45 Market Capitalization: $384.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -14.63% vs. Previous Quarter: 14.55% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -64.44 03/31/25 - -58.63 ROA 09/30/25 - - 06/30/25 - -54.24 03/31/25 - -49.74 Current Ratio 09/30/25 - - 06/30/25 - 12.39 03/31/25 - 11.06 Quick Ratio 09/30/25 - - 06/30/25 - 12.39 03/31/25 - 11.06 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 3.47 03/31/25 - 2.55 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©